| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.33B | 9.92 | 70.86 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 720.1M | 4.25 | 11.18 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 881.27M | 2.22 | -1.73 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 572.64M | 7.30 | -2.38 | -117.82% | 0.18 | |||
| NKTRNektar Therapeutics | 719.28M | 35.36 | -4.07 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IMNMImmunome, Inc. | 2.52B | 22.85 | -4.57 | -35.5% | -23.01% | -84.4% | 0.03 | |
| IBRXImmunityBio, Inc. | 3.89B | 3.95 | -6.37 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.91B | 18.86 | -6.55 | -29.15% | -292.5% | -65.76% | 0.05 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 5.79M | 12.36M | 9.6M | 13.85M | 34.48M | 9.99M |
| Revenue Growth % | - | 1.14% | -0.22% | 0.44% | 1.49% | -0.71% |
| Cost of Goods Sold | 23.64M | 34.42M | 984K | 3.64M | 3.52M | 3.93M |
| COGS % of Revenue | 4.08% | 2.78% | 0.1% | 0.26% | 0.1% | 0.39% |
| Gross Profit | 5.79M | -22.06M | 8.61M | 10.21M | 30.95M | 6.07M |
| Gross Margin % | 1% | -1.78% | 0.9% | 0.74% | 0.9% | 0.61% |
| Gross Profit Growth % | - | -4.81% | 1.39% | 0.19% | 2.03% | -0.8% |
| Operating Expenses | 40.09M | 14.06M | 75.59M | 116.61M | 147.01M | 172.68M |
| OpEx % of Revenue | 6.93% | 1.14% | 7.88% | 8.42% | 4.26% | 17.28% |
| Selling, General & Admin | 16.46M | 14.06M | 23.34M | 38.02M | 38.46M | 46.46M |
| SG&A % of Revenue | 2.84% | 1.14% | 2.43% | 2.74% | 1.12% | 4.65% |
| Research & Development | 23.64M | 34.42M | 52.26M | 82.23M | 112.08M | 130.15M |
| R&D % of Revenue | 4.08% | 2.78% | 5.44% | 5.94% | 3.25% | 13.02% |
| Other Operating Expenses | 0 | -34.42M | 0 | -3.64M | -3.52M | -3.93M |
| Operating Income | -34.3M | -36.12M | -66.98M | -106.4M | -116.06M | -166.62M |
| Operating Margin % | -5.93% | -2.92% | -6.98% | -7.68% | -3.37% | -16.67% |
| Operating Income Growth % | - | -0.05% | -0.85% | -0.59% | -0.09% | -0.44% |
| EBITDA | -33.55M | -35.22M | -66M | -104.78M | -112.53M | -162.69M |
| EBITDA Margin % | -5.8% | -2.85% | -6.88% | -7.56% | -3.26% | -16.28% |
| EBITDA Growth % | - | -0.05% | -0.87% | -0.59% | -0.07% | -0.45% |
| D&A (Non-Cash Add-back) | 751K | 900K | 984K | 1.62M | 3.52M | 3.93M |
| EBIT | -30.96M | -36.11M | -66.59M | -106.4M | -116.06M | -166.62M |
| Net Interest Income | 1.04M | 216K | 140K | 4.6M | 10.7M | 0 |
| Interest Income | 1.05M | 236K | 148K | 4.6M | 10.7M | 0 |
| Interest Expense | 4K | 20K | 8K | 0 | 0 | 0 |
| Other Income/Expense | 3.34M | -3K | 377K | 7.05M | 14.18M | 17.5M |
| Pretax Income | -30.97M | -36.13M | -66.6M | -99.35M | -101.88M | -149.11M |
| Pretax Margin % | -5.35% | -2.92% | -6.94% | -7.17% | -2.95% | -14.92% |
| Income Tax | -7.54M | -1.82M | 321K | 70K | 193K | -9K |
| Effective Tax Rate % | 0.76% | 0.95% | 1% | 1% | 1% | 1% |
| Net Income | -23.43M | -34.31M | -66.92M | -99.42M | -102.07M | -149.1M |
| Net Margin % | -4.05% | -2.78% | -6.97% | -7.18% | -2.96% | -14.92% |
| Net Income Growth % | - | -0.46% | -0.95% | -0.49% | -0.03% | -0.46% |
| Net Income (Continuing) | -23.43M | -34.31M | -66.92M | -99.42M | -102.07M | -149.1M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.85 | -1.24 | -1.11 | -1.64 | -1.38 | -1.65 |
| EPS Growth % | - | -0.46% | 0.1% | -0.48% | 0.16% | -0.2% |
| EPS (Basic) | -0.85 | -1.24 | -1.11 | -1.64 | -1.38 | -1.65 |
| Diluted Shares Outstanding | 27.66M | 27.66M | 60.26M | 60.8M | 73.81M | 90.32M |
| Basic Shares Outstanding | 27.66M | 27.66M | 60.26M | 60.8M | 73.81M | 90.32M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 57.01M | 24.31M | 391.19M | 260.25M | 338.84M | 219.38M |
| Cash & Short-Term Investments | 49.47M | 15.95M | 375.83M | 247.66M | 328.83M | 209.54M |
| Cash Only | 41.07M | 15.95M | 240.42M | 58.34M | 51.16M | 16.29M |
| Short-Term Investments | 8.4M | 0 | 135.41M | 189.32M | 277.67M | 193.24M |
| Accounts Receivable | 3.98M | 5.16M | 8.12M | 4.66M | 3.86M | 3.25M |
| Days Sales Outstanding | 251.11 | 152.37 | 308.95 | 122.91 | 40.85 | 118.73 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 373K | 423K | 671K | 1.12M | 1.22M | 1.78M |
| Total Non-Current Assets | 4.92M | 11.74M | 51.16M | 113.52M | 93.37M | 93.94M |
| Property, Plant & Equipment | 4.33M | 3.5M | 4.89M | 34.91M | 40.45M | 39.29M |
| Fixed Asset Turnover | 1.34x | 3.53x | 1.96x | 0.40x | 0.85x | 0.25x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 7.63M | 45.3M | 77.07M | 51.33M | 49.13M |
| Other Non-Current Assets | 593K | 612K | 975K | 1.54M | 1.59M | 5.52M |
| Total Assets | 61.93M | 36.05M | 442.36M | 373.76M | 432.21M | 313.31M |
| Asset Turnover | 0.09x | 0.34x | 0.02x | 0.04x | 0.08x | 0.03x |
| Asset Growth % | - | -0.42% | 11.27% | -0.16% | 0.16% | -0.28% |
| Total Current Liabilities | 10.08M | 12.39M | 25.83M | 28.13M | 28.3M | 30.65M |
| Accounts Payable | 2.54M | 2.6M | 3.99M | 1.15M | 3.12M | 2.48M |
| Days Payables Outstanding | 39.18 | 27.58 | 1.48K | 114.88 | 323.06 | 230.13 |
| Short-Term Debt | 532K | 654K | 259K | 0 | 0 | 0 |
| Deferred Revenue (Current) | 717K | 161K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 496K | 629K | 4.75M | 7.12M | 10.62M | 10.22M |
| Current Ratio | 5.66x | 1.96x | 15.15x | 9.25x | 11.97x | 7.16x |
| Quick Ratio | 5.66x | 1.96x | 15.15x | 9.25x | 11.97x | 7.16x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 44.39M | 47.09M | 28.7M | 44.77M | 35.51M | 29.71M |
| Long-Term Debt | 0 | 924K | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 26.78M | 25.91M | 25.06M |
| Deferred Tax Liabilities | 650K | 155K | 476K | 381K | 557K | 548K |
| Other Non-Current Liabilities | 42.76M | 45.08M | 6.19M | 1.65M | 2.94M | 785K |
| Total Liabilities | 54.47M | 59.48M | 54.53M | 72.89M | 63.81M | 60.36M |
| Total Debt | 532K | 1.58M | 259K | 27.75M | 27.11M | 26.49M |
| Net Debt | -40.54M | -14.38M | -240.42M | -30.59M | -24.05M | 10.19M |
| Debt / Equity | 0.07x | - | 0.00x | 0.09x | 0.07x | 0.10x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -8576.25x | -1806.20x | -8372.38x | - | - | - |
| Total Equity | 7.46M | -23.44M | 387.82M | 300.87M | 368.4M | 252.95M |
| Equity Growth % | - | -4.14% | 17.55% | -0.22% | 0.22% | -0.31% |
| Book Value per Share | 0.27 | -0.85 | 6.44 | 4.95 | 4.99 | 2.80 |
| Total Shareholders' Equity | 7.46M | -23.44M | 387.82M | 300.87M | 368.4M | 252.95M |
| Common Stock | 1K | 1K | 6K | 6K | 8K | 9K |
| Retained Earnings | 3.44M | -30.87M | -97.79M | -197.22M | -299.29M | -448.39M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | -135K | -1.52M | 30K | 255K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -32.01M | -33.22M | -32.52M | -90.97M | -93.29M | -138.2M |
| Operating CF Margin % | -5.53% | -2.69% | -3.39% | -6.57% | -2.71% | -13.83% |
| Operating CF Growth % | - | -0.04% | 0.02% | -1.8% | -0.03% | -0.48% |
| Net Income | -23.43M | -34.31M | -66.92M | -99.42M | -102.07M | -149.1M |
| Depreciation & Amortization | 751K | 900K | 984K | 3.64M | 3.52M | 3.93M |
| Stock-Based Compensation | 1.23M | 1M | 3.45M | 0 | 13.75M | 16.71M |
| Deferred Taxes | 0 | 0 | 0 | -95K | 0 | 0 |
| Other Non-Cash Items | -2.29M | -986K | 904K | 9.02M | -1.18M | -4.61M |
| Working Capital Changes | -8.27M | 177K | 29.07M | -4.11M | -7.32M | -5.11M |
| Change in Receivables | -1.09M | -1.18M | -2.96M | 3.46M | 805K | 608K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.18M | 43K | 1.14M | -2.72M | 1.82M | -354K |
| Cash from Investing | 27.23M | 6.36M | -176.4M | -93.25M | -68.18M | 86.61M |
| Capital Expenditures | -884K | -317K | -2.12M | -6.45M | -11.61M | -4.88M |
| CapEx % of Revenue | 0.15% | 0.03% | 0.22% | 0.47% | 0.34% | 0.49% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | -988K | -1M | -600K | 0 | -1.61M |
| Cash from Financing | 172K | 1.74M | 433.43M | 2.13M | 154.3M | 16.72M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 0 | 0 | 2.55M | 0 | 1.58M | 1.53M |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -32.89M | -34.53M | -35.64M | -97.42M | -104.9M | -144.71M |
| FCF Margin % | -5.68% | -2.79% | -3.71% | -7.03% | -3.04% | -14.48% |
| FCF Growth % | - | -0.05% | -0.03% | -1.73% | -0.08% | -0.38% |
| FCF per Share | -1.19 | -1.25 | -0.59 | -1.60 | -1.42 | -1.60 |
| FCF Conversion (FCF/Net Income) | 1.37x | 0.97x | 0.49x | 0.91x | 0.91x | 0.93x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 1.81M | 21K | 11K | 0 | 170K | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -313.96% | - | -36.73% | -28.87% | -30.5% | -47.99% |
| Return on Invested Capital (ROIC) | - | - | -91.46% | -38.19% | -28.32% | -41.14% |
| Gross Margin | 100% | -178.5% | 89.75% | 73.71% | 89.78% | 60.71% |
| Net Margin | -404.82% | -277.55% | -697.26% | -717.79% | -296.05% | -1491.95% |
| Debt / Equity | 0.07x | - | 0.00x | 0.09x | 0.07x | 0.10x |
| Interest Coverage | -8576.25x | -1806.20x | -8372.38x | - | - | - |
| FCF Conversion | 1.37x | 0.97x | 0.49x | 0.91x | 0.91x | 0.93x |
| Revenue Growth | - | 113.56% | -22.35% | 44.31% | 148.91% | -71.01% |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Reportable | - | - | - | 9.99M |
| Reportable Growth | - | - | - | - |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| UNITED STATES | 8.91M | 13.3M | 32.77M | 9.27M |
| UNITED STATES Growth | - | 49.25% | 146.34% | -71.71% |
| Non-US | 685K | 548K | 1.71M | 724K |
| Non-US Growth | - | -20.00% | 211.50% | -57.59% |
Caribou Biosciences, Inc. (CRBU) reported $9.3M in revenue for fiscal year 2024. This represents a 61% increase from $5.8M in 2019.
Caribou Biosciences, Inc. (CRBU) saw revenue decline by 71.0% over the past year.
Caribou Biosciences, Inc. (CRBU) reported a net loss of $157.1M for fiscal year 2024.
Caribou Biosciences, Inc. (CRBU) has a return on equity (ROE) of -48.0%. Negative ROE indicates the company is unprofitable.
Caribou Biosciences, Inc. (CRBU) had negative free cash flow of $127.7M in fiscal year 2024, likely due to heavy capital investments.